Darren W Westphal1, Ashley Eastwood2, Avram Levy3, Jane Davies4, Clare Huppatz4, Marisa Gilles5, Heather Lyttle6, Stephanie A Williams7, Gary K Dowse8. 1. Communicable Disease Control Directorate, Public and Aboriginal Health Division, Western Australia Department of Health, Perth, WA, Australia; National Centre for Epidemiology & Population Health, The Australian National University, Canberra, ACT, Australia. Electronic address: darren.westphal@health.wa.gov.au. 2. Kimberley Population Health Unit, Western Australia Country Health Service, Broome, WA, Australia. 3. PathWest Laboratory Medicine, Western Australia Department of Health, Queen Elizabeth II Medical Centre, Nedlands, WA, Australia; Faculty of Health and Medical Sciences, University of Western Australia, Crawley, WA, Australia. 4. Goldfields Population Health Unit, Western Australia Country Health Service, Kalgoorlie, WA, Australia. 5. Midwest Population Health Unit, Western Australia Country Health Service, Geraldton, WA, Australia. 6. Pilbara Population Health Unit, Western Australia Country Health Service, South Hedland, WA, Australia. 7. National Centre for Epidemiology & Population Health, The Australian National University, Canberra, ACT, Australia. 8. Communicable Disease Control Directorate, Public and Aboriginal Health Division, Western Australia Department of Health, Perth, WA, Australia.
Abstract
BACKGROUND: In 2007-08, a genotype J mumps outbreak occurred among Aboriginal people in northern Western Australia, despite high vaccine coverage. In March, 2015, a second protracted mumps outbreak occurred in northern Western Australia and spread widely across rural areas of the state. This time the outbreak was caused by a genotype G virus and again primarily affected Aboriginal people. We aimed to describe the epidemiology of this outbreak. METHODS: In this population-based surveillance study, we analysed statutory notifications and public health case follow-up data from the Western Australia Notifiable Infectious Diseases Database and vaccination information from the Australian Childhood Immunisation Register. An outbreak case of mumps was notified if the affected person was living in or visiting a community in Western Australia where there was active mumps transmission, and if mumps infection was confirmed by laboratory diagnosis or by an epidemiological link. We analysed case demographics, vaccination status, and age-standardised attack rates in Aboriginal and non-Aboriginal people by region of notification. Laboratory diagnoses were made by real-time RT-PCR, serology, or both, and carried out by the sole public pathology provider in Western Australia. FINDINGS: Between March 1, 2015, and December 31, 2016, 893 outbreak cases were notified. 798 (89%) of 893 outbreak cases were reported in Aboriginal people. 40 (4%) of 893 people were admitted to hospital, and 33 (7%) of 462 men reported orchitis. Mumps attack rates increased sharply with age, peaking in the 15-19 age group. 371 (89%) of 419 people aged 1-19 years were fully vaccinated and 29 (7%) were partly vaccinated. Of the 240 people who tested positive by real-time RT-PCR and had also been tested for mumps-specific IgG and IgM, 165 (69%) were positive for IgG but negative for IgM, indicating the importance of RT-PCR testing for diagnosis in vaccinated populations. None of the cases from the 2007-08 genotype J outbreak were re-notified. INTERPRETATION: The number of mumps outbreaks reported in recent years among highly vaccinated populations, including Indigenous populations, has been growing. More widespread and pre-emptive use of the third dose of measles, mumps, and rubella vaccine might be required to control and prevent future outbreaks in high-risk populations. Research should explore the benefit of increasing the intervals between vaccine doses to strengthen the durability of vaccine protection. FUNDING: None.
BACKGROUND: In 2007-08, a genotype J mumps outbreak occurred among Aboriginal people in northern Western Australia, despite high vaccine coverage. In March, 2015, a second protracted mumps outbreak occurred in northern Western Australia and spread widely across rural areas of the state. This time the outbreak was caused by a genotype G virus and again primarily affected Aboriginal people. We aimed to describe the epidemiology of this outbreak. METHODS: In this population-based surveillance study, we analysed statutory notifications and public health case follow-up data from the Western Australia Notifiable Infectious Diseases Database and vaccination information from the Australian Childhood Immunisation Register. An outbreak case of mumps was notified if the affected person was living in or visiting a community in Western Australia where there was active mumps transmission, and if mumps infection was confirmed by laboratory diagnosis or by an epidemiological link. We analysed case demographics, vaccination status, and age-standardised attack rates in Aboriginal and non-Aboriginal people by region of notification. Laboratory diagnoses were made by real-time RT-PCR, serology, or both, and carried out by the sole public pathology provider in Western Australia. FINDINGS: Between March 1, 2015, and December 31, 2016, 893 outbreak cases were notified. 798 (89%) of 893 outbreak cases were reported in Aboriginal people. 40 (4%) of 893 people were admitted to hospital, and 33 (7%) of 462 men reported orchitis. Mumps attack rates increased sharply with age, peaking in the 15-19 age group. 371 (89%) of 419 people aged 1-19 years were fully vaccinated and 29 (7%) were partly vaccinated. Of the 240 people who tested positive by real-time RT-PCR and had also been tested for mumps-specific IgG and IgM, 165 (69%) were positive for IgG but negative for IgM, indicating the importance of RT-PCR testing for diagnosis in vaccinated populations. None of the cases from the 2007-08 genotype J outbreak were re-notified. INTERPRETATION: The number of mumps outbreaks reported in recent years among highly vaccinated populations, including Indigenous populations, has been growing. More widespread and pre-emptive use of the third dose of measles, mumps, and rubella vaccine might be required to control and prevent future outbreaks in high-risk populations. Research should explore the benefit of increasing the intervals between vaccine doses to strengthen the durability of vaccine protection. FUNDING: None.
Authors: Kevin J McHugh; Lihong Jing; Sean Y Severt; Mache Cruz; Morteza Sarmadi; Hapuarachchige Surangi N Jayawardena; Collin F Perkinson; Fridrik Larusson; Sviatlana Rose; Stephanie Tomasic; Tyler Graf; Stephany Y Tzeng; James L Sugarman; Daniel Vlasic; Matthew Peters; Nels Peterson; Lowell Wood; Wen Tang; Jihyeon Yeom; Joe Collins; Philip A Welkhoff; Ari Karchin; Megan Tse; Mingyuan Gao; Moungi G Bawendi; Robert Langer; Ana Jaklenec Journal: Sci Transl Med Date: 2019-12-18 Impact factor: 17.956
Authors: Hua Zhu; Han Zhao; Rong Ou; Haiyan Xiang; Ling Hu; Dan Jing; Manoj Sharma; Mengliang Ye Journal: Int J Environ Res Public Health Date: 2019-08-22 Impact factor: 3.390